BMC Cancer

1. YU G, Wei F, Li W, Guo Q, et al
   FAM111B knockdown attenuates tumorigenesis of ovarian cancer via the downregulation of MYC.
   BMC Cancer. 2025;25:1290.
   

   >> Share

   
   

   
   Clin Cancer Res

2. RICHARDSON DL, Quintanilha JCF, Danziger N, Li G, et al
   Correction: Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
   Clin Cancer Res. 2025;31:3599.
   

   >> Share

   
   

   
   Eur J Obstet Gynecol Reprod Biol

3. ROY M, Pace-Loscos T, Schiappa R, Delotte J, et al
   Therapeutic impact of eras protocol implementation in cytoreductive surgery for ovarian cancer.
   Eur J Obstet Gynecol Reprod Biol. 2025;313:114622.
   

   >> Share

   
   

   
   Gynecol Oncol

4. SIA TY, Moufarrij S, Milani J, Kane S, et al
   Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?
   Gynecol Oncol. 2025;201:60-68.
   

   >> Share

   
   
5. BRUBAKER LW, Merritt MA
   Ovarian cancer health disparities: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
   Gynecol Oncol. 2025;201:56-59.
   

   >> Share

   
   
6. APOSTOL AI, Kotsopoulos J, Gronwald J, Kim RH, et al
   Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.
   Gynecol Oncol. 2025;201:44-52.
   

   >> Share

   
   
7. CHATOR C, Chevrier M, Frenel JS, Guyon F, et al
   Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.
   Gynecol Oncol. 2025;201:17-25.
   

   >> Share

   
   

   
   J Natl Cancer Inst

8. MAJIDI A, Rinaldi S, Biessy C, Vozar B, et al
   Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study.
   J Natl Cancer Inst. 2025 Aug 14:djaf222. doi: 10.1093.
   

   >> Share

   
   

   
   Mol Ther Oncol

9. TZENG YM, Khine AA, Huang HS, Chu TY, et al
   Ovatodiolide triggers ferroptosis in high-grade serous ovarian cancer through HMOX1 upregulation.
   Mol Ther Oncol. 2025;33:201023.
   

   >> Share

   
   

   
   Oncogene

10. LI Q, Zhang S, Wang M, Yi Q, et al
    Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522.
    

    >> Share

    
    

    
    Oncol Rep

11. LU DH, Yang J, Gao LK, Min J, et al
    [Expression of Concern] Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
    Oncol Rep. 2025;54:138.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share